Mabwell moves 9MW2821 into Phase III TNBC testing
Bottom line
Mabwell has started a Phase III trial of 9MW2821, its Nectin-4-targeting antibody-drug conjugate, in locally advanced or metastatic triple-negative breast cancer after prior taxane-based chemotherapy, with or without immunotherapy, and a topoisomerase inhibitor-based ADC. The company said April 23, 2026, that the randomized, open-label, multicenter study will compare 9MW2821 against investigator’s choice chemotherapy, and described it as the first Nectin-4 ADC to reach Phase III in TNBC. Mabwell has also been building a broader late-stage program around the asset, which is already in pivotal studies in urothelial and cervical cancers, and began a U.S. TNBC study in August 2025 with the first patient dosed at Memorial Sloan Kettering Cancer Center. (mabwell.com)
Why it matters: For veterinary professionals, this isn’t a practice-changing animal health story, but it is a useful signal from the oncology drug-development pipeline. ADC development continues to move quickly, and this trial highlights how companies are trying to address a tough post-ADC setting where standard options often fall back to chemotherapy. Earlier Mabwell-reported TNBC data suggested antitumor activity for 9MW2821, with 20 efficacy-evaluable patients showing a 50.0% objective response rate, 80.0% disease control rate, and median progression-free survival of about 5.8 to 5.9 months, though those results came from a small, noncomparative dataset and need confirmation in Phase III. Broader oncology commentary has also emphasized that sequencing after prior ADC therapy remains an unmet need, with second ADCs often producing shorter benefit than the first. (www1.hkexnews.hk)
What to watch: Watch for trial registration details, enrollment milestones, and whether Phase III results can validate the early TNBC signal in a post-ADC population with few established options. (mabwell.com)
Mabwell has initiated a Phase III clinical trial of 9MW2821 in triple-negative breast cancer, pushing its Nectin-4-targeting ADC into a new late-stage setting where treatment options are limited after prior taxane-based therapy and a topoisomerase inhibitor-based ADC. In its April 23, 2026 announcement, the company said the randomized, open-label, controlled, multicenter study will compare 9MW2821 with investigator’s choice chemotherapy in patients with locally advanced or metastatic TNBC, and called it the first Nectin-4 ADC to enter Phase III for this indication. (mabwell.com)
The move builds on a development program that has been expanding across several solid tumors. Mabwell has already advanced 9MW2821 into Phase III trials in cervical cancer and urothelial carcinoma, and the company’s R&D timeline shows TNBC had been on the roadmap for some time, including NMPA approval in July 2024 for a TNBC clinical trial and FDA Fast Track designation that same month for locally advanced or metastatic Nectin-4-positive TNBC. The company also dosed the first patient in a U.S. TNBC study in August 2025, marking its first overseas clinical study for the asset. (mabwell.com)
The new Phase III study is aimed squarely at a hard-to-treat population: patients whose disease has already been exposed to taxane-based chemotherapy and an ADC carrying a topoisomerase inhibitor payload. Mabwell said that, in this setting, chemotherapy remains the main fallback option, underscoring the unmet need it’s trying to address. The company positions 9MW2821, also called bulumtatug fuvedotin, as a next-generation Nectin-4 ADC built with site-specific conjugation technology and an MMAE payload. Unlike some biomarker-driven programs, Mabwell has previously said its TNBC studies do not require biomarker screening, citing high Nectin-4 expression in TNBC. (mabwell.com)
Early data are part of the rationale for moving forward. At the 2024 ASCO annual meeting, investigators reported Phase I/IIa results for 9MW2821 across advanced solid tumors, including TNBC. In the TNBC subgroup, the ASCO abstract listed 16 patients with an objective response rate of 43.8%. In later company disclosures, Mabwell reported that among 20 efficacy-evaluable patients with advanced TNBC treated at 1.25 mg/kg, objective response rate was 50.0%, disease control rate was 80.0%, median progression-free survival was 5.8 to 5.9 months, median duration of response was 4.0 months, and median overall survival was 14.2 months. Those figures are encouraging, but they come from early-stage, nonrandomized experience and should be interpreted cautiously until the Phase III comparator data arrive. (s3.amazonaws.com)
Outside reaction specific to this Mabwell trial appears limited so far, but the broader breast cancer field has been vocal about the challenge this program is targeting. In a 2026 interview with Targeted Oncology, Dana-Farber’s Ana Garrido-Castro said sequential ADC use often leads to shorter time to progression with the second ADC, and noted that the field still needs better understanding of whether resistance reflects target loss, payload resistance, or other mechanisms. That framing helps explain why a late-stage study in post-ADC TNBC is getting attention: it’s testing whether a different target and payload strategy can extend benefit after current ADC options stop working. (targetedonc.com)
Why it matters: For veterinary professionals, the direct clinical impact is limited because this is a human oncology development, not a companion animal therapeutic. Still, it’s relevant as a window into where translational oncology is heading. ADC platforms, biomarker strategy, trial design in refractory disease, and the economics of late-line cancer care increasingly shape the broader oncology ecosystem, including comparative oncology research and the expectations pet parents may bring to specialty cancer discussions. It also reinforces a larger industry point: once patients progress after an ADC, the next step is still unsettled, and developers are racing to define what comes after today’s standards. (mabwell.com)
There’s also a competitive angle. Enfortumab vedotin, the best-known Nectin-4 ADC, has shown modest activity in TNBC cohorts, with publicly cited figures around a 19% objective response rate and progression-free survival of roughly 3.5 months, though cross-trial comparisons are inherently limited. Mabwell has pointed to stronger early numbers for 9MW2821, but that remains a hypothesis until tested head-to-head against contemporary control therapy in Phase III. If the study reads out positively, it could sharpen interest in Nectin-4 beyond urothelial cancer and further crowd the ADC landscape in breast cancer. (www1.hkexnews.hk)
What to watch: Next steps include formal trial registration details, site activation and enrollment pace, any interim safety disclosures, and whether Mabwell can translate early single-arm TNBC activity into a statistically persuasive Phase III result in a post-ADC population. (mabwell.com)